Alnylam Pharmaceuticals (ALNY) Analyst & Key Data

Analyst Consensus

Buy44 analysts

Buy

Updated Sep 12, 2026

Total Analysts44

Strong Buy

1

Buy

38

Hold

12

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

B

DCF Score4.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score5.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$248.68

Median Target+72.37%

$428.64

Potential upside vs current price

Current Stock Price

$248.68

Median Target+72.37%

$428.64

Potential upside vs current price

Analyst Consensus

Buy44 analysts

Buy

Updated Sep 12, 2026

Total Analysts44

Strong Buy

1

Buy

38

Hold

12

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

B

DCF Score4.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score5.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$248.68

Median Target+72.37%

$428.64

Potential upside vs current price

Current Stock Price

$248.68

Median Target+72.37%

$428.64

Potential upside vs current price

Alnylam Pharmaceuticals, Inc.